Expert opinion in biological therapy: update on developments in lung gene transfer

被引:18
作者
Griesenbach, Uta [3 ]
Alton, Eric W. F. W. [1 ,2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Gene Therapy, London SW3 6LR, England
[2] UK Cyst Fibrosis Gene Therapy Consortium, London, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Gene Therapy, London SW3 6LR, England
关键词
acute lung injury; airways; alpha 1-antitrypsin deficiency; asthma; chronic obstructive pulmonary disease; cystic fibrosis; gene therapy; lung infection; lung transplantation; non-viral gene transfer agents; primary ciliary dyskinesia; surfactant protein B deficiency; viral gene transfer agents; TRANSMEMBRANE CONDUCTANCE REGULATOR; RECOMBINANT ADENOASSOCIATED VIRUS; SUSTAINED TRANSGENE EXPRESSION; KERATINOCYTE GROWTH-FACTOR; CPG-FREE PLASMIDS; CYSTIC-FIBROSIS; AIRWAY EPITHELIUM; IN-VIVO; SENDAI-VIRUS; DIRECTED EVOLUTION;
D O I
10.1517/14712598.2013.735656
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Gene therapy may be suitable for a large number of acquired and inherited lung diseases, and research efforts in the field are vast. Although gene transfer to the lung has proven more challenging than initially anticipated, significant progress has been made over the last 10 years. Areas covered: Here, we will first review viral and non-viral gene transfer agents that have been assessed for lung gene therapy and discuss key barriers to pulmonary gene transfer. We will then review progress in gene therapy for various lung diseases. Expert opinion: In our view, one of the most significant developments in recent years is the generation of lentiviral vectors which efficiently transduce lung tissue. Focused and coordinated efforts assessing lentivirus safety and scaling up lentivirus production will be required to move this vector into clinical lung gene therapy studies. Although market authorization for a lung gene therapy product is not yet available, we are optimistic that this key milestone can be achieved in the next few years.
引用
收藏
页码:345 / 360
页数:16
相关论文
共 50 条
  • [41] Gene therapy of the central nervous system: General considerations on viral vectors for gene transfer into the brain
    Serguera, C.
    Bemelmans, A. -P.
    REVUE NEUROLOGIQUE, 2014, 170 (12) : 727 - 738
  • [42] An expert system for diagnosis and therapy in lung transplantation
    Prasad, BN
    Finkelstein, SM
    Hertz, MI
    COMPUTERS IN BIOLOGY AND MEDICINE, 1996, 26 (06) : 477 - 488
  • [43] Gene therapy developments for pancreatic cancer
    Bhattacharrya, M
    Lemoine, NR
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2006, 20 (02) : 285 - 298
  • [44] Recent developments in ocular gene therapy
    Borrás, T
    EXPERIMENTAL EYE RESEARCH, 2003, 76 (06) : 643 - 652
  • [45] The ethics of gene therapy and abortion: Public opinion
    Evans, MDR
    Kelley, J
    Zanjani, ED
    FETAL DIAGNOSIS AND THERAPY, 2005, 20 (03) : 223 - 234
  • [46] Adeno associated viral vectors for gene transfer and gene therapy
    Büeler, H
    BIOLOGICAL CHEMISTRY, 1999, 380 (06) : 613 - 622
  • [47] Cancer gene therapy: developments to 2000
    Bateman, AR
    Harrington, KJ
    Melcher, AA
    Vile, RG
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (12) : 2799 - 2813
  • [48] Update on gene therapy for hemoglobin disorders
    Persons, DA
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2003, 5 (05) : 508 - 516
  • [49] Retroviral vectors and gene therapy: An update
    Maurya, S. K.
    Srivastava, Sushant
    Joshi, R. K.
    INDIAN JOURNAL OF BIOTECHNOLOGY, 2009, 8 (04): : 349 - 357
  • [50] Gene therapy in the cardiovascular system: an update
    Sinnaeve, P
    Varenne, O
    Collen, D
    Janssens, S
    CARDIOVASCULAR RESEARCH, 1999, 44 (03) : 498 - 506